MARKET

BCRX

BCRX

Biocryst Pharmaceuticals Inc
NASDAQ
7.58
+0.17
+2.29%
After Hours: 7.58 0 0.00% 16:10 01/06 EST
OPEN
7.38
PREV CLOSE
7.41
HIGH
7.63
LOW
7.36
VOLUME
4.98M
TURNOVER
--
52 WEEK HIGH
11.31
52 WEEK LOW
6.00
MARKET CAP
1.60B
P/E (TTM)
-160.2537
1D
5D
1M
3M
1Y
5Y
1D
BioCryst Grants Inducement RSUs to New Employee
Reuters · 12h ago
BIOCRYST REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 12h ago
Weekly Report: what happened at BCRX last week (1229-0102)?
Weekly Report · 1d ago
Weekly Report: what happened at BCRX last week (1222-1226)?
Weekly Report · 12/29/2025 09:49
BioCryst Pharmaceuticals (BCRX) Is Up 8.0% After FDA Clears First Oral HAE Prophylaxis For Children
Simply Wall St · 12/25/2025 03:52
Astria Therapeutics to Be Acquired by BioCryst Pharmaceuticals
Reuters · 12/23/2025 22:16
BioCryst Chief Legal Officer Alane P. Barnes Reports Disposal of Common Shares
Reuters · 12/23/2025 21:12
TD Cowen Reaffirms Their Buy Rating on BioCryst (BCRX)
TipRanks · 12/23/2025 11:35
More
About BCRX
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on improving the lives of people living with hereditary angioedema and other rare diseases. The Company leverages its expertise in designing to develop first-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. The RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older.

Webull offers BioCryst Pharmaceuticals Inc stock information, including NASDAQ: BCRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BCRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BCRX stock methods without spending real money on the virtual paper trading platform.